Snapshot
- Ticker: COMP (NYSE)
- Bucket: Consumer, Fintech & Housing
- Q1 2026 position: $40.7M — 5,561,998 common shares, 0.81% of 13F
- HQ: New York, New York
- What it does: Largest US residential real-estate brokerage by sales volume; now combining with Anywhere Real Estate (Coldwell Banker, Century 21, Sotheby’s International Realty) to add franchising, title/escrow, and relocation.
Business Overview
Compass built the #1 US brokerage by recruiting top agents onto a proprietary technology platform and rolling up regional brokerages. In September 2025 it signed an all-stock merger with Anywhere Real Estate valued at ~10B including assumed debt), with Compass holders owning ~78% of the combined company. The deal diversifies Compass beyond commission revenue into Anywhere’s franchise royalties, title and escrow, and relocation businesses — over $1B of higher-margin revenue.
Standalone 2025 was a record year despite a still-frozen housing market: full-year revenue of 1.70B (+23.1% YoY, 11.3% organic), record full-year adjusted EBITDA, and 2.70B (+99% YoY; pro forma +7% to 61M, and 2.70–2.75B and expects positive free cash flow for the full year.
Financial Trajectory
| Period | Revenue | Notes |
|---|---|---|
| FY2024 | ~$5.6B | Existing-home sales near multi-decade lows |
| FY2025 | $7.0B | Record year; record adj. EBITDA, $217M op. cash flow |
| Q1 2026 | $2.70B | +99% YoY (Anywhere consolidated); pro forma +7% |
Why Atreides Owns It
Compass is the transaction-volume leg of Atreides’ housing-recovery basket (with Rocket on financing and Ferguson on building products). The leverage is mechanical: existing-home transactions have been running ~30%+ below normalized levels since 2022; if mortgage rates decline and turnover mean-reverts, brokerage commissions scale with volume against a cost base management has held flat for years. The Anywhere merger adds counter-cyclical franchise/title cash flows and synergy optionality (deal underwritten at ~10x Anywhere’s 2026 EBITDA, 6.5x fully synergized).
The position is new as of Q4 2025 — initiated at $92M shortly after the Anywhere deal was announced — and was trimmed by ~36% of shares into Q1 2026. As with Rocket, the housing thesis is inferred from portfolio construction; Baker’s public 2025-26 commentary has focused on AI/semis rather than housing specifically.
Position History
| Quarter | Type | Shares/Notional | Value | % of 13F |
|---|---|---|---|---|
| Q4 2024 | — | not held | — | — |
| Q1 2025 | — | not held | — | — |
| Q2 2025 | — | not held | — | — |
| Q3 2025 | — | not held | — | — |
| Q4 2025 | Common | 8,723,434 | $92,206,697 | 1.13% |
| Q1 2026 | Common | 5,561,998 | $40,658,205 | 0.81% |
A new Q4 2025 position of 8.7M shares (92M to $41M reflects both the ~36% share reduction and a meaningful decline in the stock price over the quarter — Atreides took some exposure off but kept a substantial residual position in the recovery thesis.
Risks
- Housing turnover stays depressed: the “lock-in effect” persists as long as existing mortgages sit far below market rates.
- Merger integration: combining the largest brokerage with Anywhere’s franchise network is a multi-year execution job (deal announced September 2025 with close initially expected H2 2026, but Anywhere’s revenue was already consolidated in Q1 2026 results, indicating an earlier close).
- Commission compression: post-NAR-settlement changes to buyer-agent compensation structures could shrink the industry fee pool.
- Anywhere brings substantial debt into the combined capital structure.
- Agent economics: Compass’s model historically burned cash on recruiting incentives; a price war for top agents could resume.
Sources
- https://investors.compass.com/news/news-details/2026/Compass-Inc—Reports-Record-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx
- https://www.sec.gov/Archives/edgar/data/0001563190/000156319026000094/exhibit9918-k1q26pr.htm
- https://www.sec.gov/Archives/edgar/data/0001398987/000119312525210057/d26146dex991.htm
- https://www.stocktitan.net/sec-filings/COMP/8-k-compass-inc-reports-material-event-319707b6db7a.html